Elite Pharmaceuticals vs. Aytu: Which CNS Stock Is the Better Buy?Zacks Investment Research · Oct 7, 2026
Aytu BioPharma, Inc. (AYTU) Q4 2026 Earnings Call TranscriptSeeking Alpha · Sep 22, 2026
Aytu BioPharma, Inc. (AYTU) Reports Q4 Loss, Beats Revenue EstimatesZacks Investment Research · Sep 22, 2026
Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial ResultsAccesswire · Sep 22, 2026
Aytu BioPharma to Report Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results on September 22, 2026Accesswire · Sep 16, 2026
AWM Investment Company Inc. Invests $1.33 Million in Aytu BioPharma Inc. $AYTUDefense World · Aug 26, 2026Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 22, 2026 | -$0.29 | -$0.05 | Beat |
| May 13, 2026 | -$0.31 | -$0.53 | Miss |
| Feb 3, 2026 | -$0.26 | -$1.05 | Miss |
| Nov 13, 2025 | -$0.06 | -$0.08 | Miss |
| Sep 23, 2025 | -$0.02 | -$2.92 | Miss |
| May 14, 2025 | -$0.17 | $0.20 | Beat |